S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
S&P 500   5,022.21
DOW   37,753.31
QQQ   425.84
ASML Fires Warning Shot For Tech Investors
Checking in with 5 Bitcoin Stocks Ahead of Bitcoin's Halving
Closing prices for crude oil, gold and other commodities
Lululemon’s P/E Is Back to 2017 Levels: Should You Buy the Dip?
Abbott Laboratories Outlook is Healthy: Buy the Dip
Prologis Stock Leading U.S. Logistics Boom
Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
NASDAQ:CHRS

Coherus BioSciences (CHRS) Stock Price, News & Analysis

$2.15
0.00 (0.00%)
(As of 04/17/2024 ET)
Today's Range
$2.12
$2.22
50-Day Range
$2.15
$2.85
52-Week Range
$1.43
$8.34
Volume
1.26 million shs
Average Volume
3.90 million shs
Market Capitalization
$242.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.29

Coherus BioSciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
331.9% Upside
$9.29 Price Target
Short Interest
Healthy
20.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
0.63mentions of Coherus BioSciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.56) to $0.11 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.16 out of 5 stars

Medical Sector

140th out of 913 stocks

Biological Products, Except Diagnostic Industry

13th out of 134 stocks

CHRS stock logo

About Coherus BioSciences Stock (NASDAQ:CHRS)

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

CHRS Stock Price History

CHRS Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Q4 2023 Coherus BioSciences Inc Earnings Call
Recap: Coherus BioSciences Q4 Earnings
See More Headlines
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/13/2024
Today
4/17/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CHRS
Fax
N/A
Employees
306
Year Founded
2010

Price Target and Rating

Average Stock Price Target
$9.29
High Stock Price Target
$12.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+331.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-237,890,000.00
Pretax Margin
-92.62%

Debt

Sales & Book Value

Annual Sales
$257.24 million
Book Value
($1.74) per share

Miscellaneous

Free Float
100,327,000
Market Cap
$242.33 million
Optionable
Optionable
Beta
0.54

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Dennis M. LanfearMr. Dennis M. Lanfear (Age 69)
    Chairman, President & CEO
    Comp: $1.79M
  • Mr. Bryan J. McMichael (Age 46)
    Interim CFO, Principal Financial and Accounting Officer, SVP-Accounting & Corporate Controller
  • Mr. Richard L. Hameister
    Chief Technical Officer
  • Ms. Jami Taylor
    Vice President of Investor Relations
  • Cheston Turbyfill
    Vice President of Communications
  • Mr. Scott Saywell
    Executive Vice President of Corporate Development
  • Ms. Rebecca Sunshine (Age 61)
    Chief Human Resources Officer
  • Mr. Michael Chen
    Senior Vice President of Commercial Analytics & Trade
  • Mr. Paul Reider (Age 55)
    Chief Commercial Officer
  • Dr. Theresa M. Lavallee Ph.D. (Age 58)
    Chief Development Officer & Chairman of Scientific Advisory Board

CHRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CHRS shares.
View CHRS analyst ratings
or view top-rated stocks.

What is Coherus BioSciences' stock price target for 2024?

6 brokerages have issued 12-month price targets for Coherus BioSciences' shares. Their CHRS share price targets range from $6.00 to $12.00. On average, they anticipate the company's stock price to reach $9.29 in the next twelve months. This suggests a possible upside of 331.9% from the stock's current price.
View analysts price targets for CHRS
or view top-rated stocks among Wall Street analysts.

How have CHRS shares performed in 2024?

Coherus BioSciences' stock was trading at $3.33 at the beginning of the year. Since then, CHRS shares have decreased by 35.4% and is now trading at $2.15.
View the best growth stocks for 2024 here
.

Are investors shorting Coherus BioSciences?

Coherus BioSciences saw a decrease in short interest in March. As of March 31st, there was short interest totaling 23,450,000 shares, a decrease of 9.5% from the March 15th total of 25,910,000 shares. Based on an average daily volume of 3,790,000 shares, the short-interest ratio is currently 6.2 days.
View Coherus BioSciences' Short Interest
.

When is Coherus BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our CHRS earnings forecast
.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) released its earnings results on Wednesday, March, 13th. The biotechnology company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by $0.39. The biotechnology company earned $91.52 million during the quarter, compared to analyst estimates of $105.30 million.

What ETFs hold Coherus BioSciences' stock?

ETFs with the largest weight of Coherus BioSciences (NASDAQ:CHRS) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA) and First Trust Innovation Leaders ETF (ILDR).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.17%) and RFG Advisory LLC (0.05%). Insiders that own company stock include Dennis M Lanfear, James Healy and Mcdavid Stilwell.
View institutional ownership trends
.

How do I buy shares of Coherus BioSciences?

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Coherus BioSciences have any subsidiaries?
The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More
This page (NASDAQ:CHRS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners